The Scripps Research Institute

Dana-farber-cancer Institute Inc.

Irm LLC

Other

Novartis Ag

Barun Okram

Nathanael Schiander Gray

Xianming Deng

Jianming Zhang

Jae Won Chang

Pingda Ren

Xu Wu

Yahua Liu

Tetsuo Uno

Truc Ngoc Nguyen

Qiang Ding

Jianwei Che

Guobao Zhang

Yongping Xie

Hong Liu

Pierre-Yves Michellys

Xiaohui He

Robert Epple

Rodrigo Rodriguez

Ayako Honda

Baogen Wu

Bei Chen

Ha-Soon Choi

Kunyong Yang

Yunho Jin

Xuefeng Zhu

Mihai Azimioara

Xia Wang

Duncan Shaw

Amy Wojciechowski

Victor Ivanovich Nikulin

Hasnain Ahmed Malik

Qihui Jin

Xueshi Hao

Sejal Patel

Philip Lam

S Frank Yan

Declan Hardy

Yiping Shen

Fabio Meier

The present disclosure provides novel heteroaryl compounds of formula (VII). Such compounds are useful for the treatment of cancers.

Small molecule myristate inhibitors of Bcr-abl and methods of use

The present disclosure provides novel heteroaryl compounds of formula (IV). Such compounds are useful for the treatment of cancers. 

The present invention provides novel heteroaryl compounds of formula (I) having a pyrimidine-containing core that is linked to a 4-trifluoromethoxyphenyl group via an amine linker. Such compounds are useful for the treatment of cancers. 

Small molecule myristate inhibitors of BCR-ABL and methods of use

Provided herein are a novel class of compounds of Formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.

Compounds and compositions as Syk kinase inhibitors

The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC-GR-1R, Alk, c-FMS, or combinations thereof.

Compounds and compositions as kinase inhibitors

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFR&#x3b1;, Ros, SAPK2&#x3b1;, SGK, SIK, Syk, Tie2 and TrkB kinases.

Compounds and compositions as protein kinase inhbitors

The invention provides a novel class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-AbI, Aurora-A, SGK, Tie-2, Trk-B, FGFR3, c-kit, b-RAF, c-RAF, DYRK2, Fms, Fyn and PDGFRalpha and PDGFR&bgr; kinases. 

Compounds and compositions as protein kinase inhibitors

Growing community of inventors

San Diego, CA, United States of America

Barun Okram